| Date: | 2007-02-01 |
| Acquiring pharma company: | AstraZeneca (UK) |
| Acquired biotech company: | Arrow Therapeutics (UK) |
| Amount: | $150 million in cash |
| Terms of the agreement: | |
| Other: | After Cambridge Antibody Technology (CAT) last May, this is the second major acquisition in less than a year by AstraZeneca for reinforcing its R&D capacities. The acquisition of Arrow Therapeutics is part of its development strategy in infectious disease. AstraZeneca thus adds a series of antivirals to its portfolio, notably with several programmes against the hepatitis C virus (A-831) and respiratory syncytial virus (RSV604). |
